None listed
Conditions
Brief summary
This study hypothesises that shorter duration low molecular weight therpay is as effective as standard therapy in post operative orthopaedic DVT prophylaxis. There will be no significant difference in the incidence of post operative thrombotic events such as DVTs and PE. There mat be added advantages of reduced leg swelling and hence pain with the use of mobile calf compressor device as an outpatient.
Interventions
The usual practice of low molecular heparin therapy after orthopedic surgery to reduce risk of DVT and PE remains controversial in terms of length of therapy. This study is aimed at answering this question by reducing the length of therapy from 2 weeks to 1 week, without compromising safety in terms of increasing risk of clotting complications. The usual therapy involves enoxaparim 0.5 mg/kg,daily, commencing 8-12 hours post op, given subcutaneously. The only difference between the study groups
The usual practice of low molecular heparin therapy after orthopedic surgery to reduce risk of DVT and PE remains controversial in terms of length of therapy. This study is aimed at answering this question by reducing the length of therapy from 2 weeks to 1 week, without compromising safety in terms of increasing risk of clotting complications. The usual therapy involves enoxaparim 0.5 mg/kg,daily, commencing 8-12 hours post op, given subcutaneously. The only difference between the study groups was the length of the therapy but given daily.
Sponsors
Southern Sydney Hematology
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
age 18-90 no personal/family hx thrombophilia BMI <35 english speaking no anti-coagulation for other reasons no acute clotting problem undergoing elective total knee replacement surgery
Exclusion criteria
age <18, >90 BMI >35 known history of thrombophilia already on anti-coagulation active malignancy or bleeding disorders unfit to undergo surgical procedure (TKR)
Outcome results
None listed